[CTLA4-Ig].
Miyasaka
Nobuyuki
N
Department of Medicine & Rheumatology, Tokyo Medical & Dental University.
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins; D008727:Methotrexate / Q000627:therapeutic use; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; C497964:CD86 protein, human; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D000069594:Abatacept; D008727:Methotrexate